Karen B. Addison

Array ( [id] => 19234037 [patent_doc_number] => 20240191229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => RNA SILENCING AGENTS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/286640 [patent_app_country] => US [patent_app_date] => 2022-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9975 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19693228 [patent_doc_number] => 20250011773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING TDP-43 PROTEINOPATHY [patent_app_type] => utility [patent_app_number] => 18/285802 [patent_app_country] => US [patent_app_date] => 2022-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -102 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18285802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18311030 [patent_doc_number] => 20230114930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => Compounds and Methods for Reducing LRRK2 Expression [patent_app_type] => utility [patent_app_number] => 17/712822 [patent_app_country] => US [patent_app_date] => 2022-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17712822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232265 [patent_doc_number] => 20240189457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => GENE THERAPY FOR TREATING BETA-HEMOGLOBINOPATHIES [patent_app_type] => utility [patent_app_number] => 18/553729 [patent_app_country] => US [patent_app_date] => 2022-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18294439 [patent_doc_number] => 20230104125 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER [patent_app_type] => utility [patent_app_number] => 17/709539 [patent_app_country] => US [patent_app_date] => 2022-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749944 [patent_doc_number] => 20220228149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA [patent_app_type] => utility [patent_app_number] => 17/709087 [patent_app_country] => US [patent_app_date] => 2022-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432916 [patent_doc_number] => 20240301414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => MICRORNA-134 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/552335 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172815 [patent_doc_number] => 20240158789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => NUCLEIC ACIDS SIMULTANEOUSLY INHIBITING EXPRESSION OF C-MET GENE AND PD-L1 GENE [patent_app_type] => utility [patent_app_number] => 18/281539 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18281539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19181211 [patent_doc_number] => 11987794 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => Products and compositions [patent_app_type] => utility [patent_app_number] => 17/688789 [patent_app_country] => US [patent_app_date] => 2022-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 33 [patent_no_of_words] => 26503 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 205 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17836390 [patent_doc_number] => 20220273695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => MCM FOR GENE THERAPY TO ACTIVATE WNT PATHWAY [patent_app_type] => utility [patent_app_number] => 17/683699 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17683699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738503 [patent_doc_number] => 12215322 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors [patent_app_type] => utility [patent_app_number] => 17/680940 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37221 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18972280 [patent_doc_number] => 20240052372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => ALLELE-SPECIFIC GENOME EDITING OF THE NR2E3 MUTATION G56R [patent_app_type] => utility [patent_app_number] => 18/278494 [patent_app_country] => US [patent_app_date] => 2022-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18278494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142517 [patent_doc_number] => 20240141359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => GENOME EDITING FOR TREATING MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 18/278338 [patent_app_country] => US [patent_app_date] => 2022-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18278338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172451 [patent_doc_number] => 20240158425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => MODIFIED ADENINES [patent_app_type] => utility [patent_app_number] => 18/277474 [patent_app_country] => US [patent_app_date] => 2022-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897421 [patent_doc_number] => 20220307083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT [patent_app_type] => utility [patent_app_number] => 17/670937 [patent_app_country] => US [patent_app_date] => 2022-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096507 [patent_doc_number] => 20240115734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY [patent_app_type] => utility [patent_app_number] => 18/264919 [patent_app_country] => US [patent_app_date] => 2022-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -203 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17930220 [patent_doc_number] => 20220325345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => Methods and Compositions for Assessing Patients with Preeclampsia-Related Conditions Using MicroRNA [patent_app_type] => utility [patent_app_number] => 17/592818 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12034 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19656888 [patent_doc_number] => 20240423953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => METHODS AND COMPOSITIONS FOR TARGETING SV2 PROTEINS FOR IMMUNE REGULATION [patent_app_type] => utility [patent_app_number] => 18/262890 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18262890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081933 [patent_doc_number] => 20240108734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => METHODS FOR TREATING AND AMELIORATING CANCER [patent_app_type] => utility [patent_app_number] => 18/273716 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18065691 [patent_doc_number] => 20220396778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => Novel RNA Composition and Production Method for Use in iPS Cell Generation [patent_app_type] => utility [patent_app_number] => 17/648340 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17648340 [rel_patent_id] =>[rel_patent_doc_number] =>)